WallStSmart

EOG Resources Inc (EOG)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Gilead Sciences Inc generates 25% more annual revenue ($29.44B vs $23.57B). GILD leads profitability with a 28.9% profit margin vs 23.3%. GILD appears more attractively valued with a PEG of 0.38. EOG earns a higher WallStSmart Score of 80/100 (A-).

EOG

Exceptional Buy

80

out of 100

Grade: A-

Growth: 6.7Profit: 8.5Value: 8.0Quality: 5.8
Piotroski: 2/9Altman Z: 2.87

GILD

Strong Buy

72

out of 100

Grade: B

Growth: 5.3Profit: 9.5Value: 8.7Quality: 5.5
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EOGUndervalued (+51.4%)

Margin of Safety

+51.4%

Fair Value

$243.17

Current Price

$130.03

$113.14 discount

UndervaluedFair: $243.17Overvalued
GILDUndervalued (+43.2%)

Margin of Safety

+43.2%

Fair Value

$236.08

Current Price

$131.33

$104.75 discount

UndervaluedFair: $236.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EOG6 strengths · Avg: 8.7/10
Operating MarginProfitability
37.9%10/10

Strong operational efficiency at 37.9%

Market CapQuality
$69.26B9/10

Large-cap with strong market position

Profit MarginProfitability
23.3%9/10

Keeps 23 of every $100 in revenue as profit

P/E RatioValuation
12.8x8/10

Attractively priced relative to earnings

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

GILD6 strengths · Avg: 9.3/10
PEG RatioValuation
0.3810/10

Growing faster than its price suggests

Return on EquityProfitability
40.7%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
37.4%10/10

Strong operational efficiency at 37.4%

Market CapQuality
$166.40B9/10

Large-cap with strong market position

Profit MarginProfitability
28.9%9/10

Keeps 29 of every $100 in revenue as profit

EPS GrowthGrowth
23.4%8/10

Earnings expanding 23.4% YoY

Areas to Watch

EOG1 concerns · Avg: 3.0/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

GILD1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : EOG

The strongest argument for EOG centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 23.3% and operating margin at 37.9%. Revenue growth of 15.6% demonstrates continued momentum.

Bull Case : GILD

The strongest argument for GILD centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 28.9% and operating margin at 37.4%. PEG of 0.38 suggests the stock is reasonably priced for its growth.

Bear Case : EOG

The primary concerns for EOG are Piotroski F-Score.

Bear Case : GILD

The primary concerns for GILD are Revenue Growth.

Key Dynamics to Monitor

EOG profiles as a growth stock while GILD is a value play — different risk/reward profiles.

GILD carries more volatility with a beta of 0.33 — expect wider price swings.

EOG is growing revenue faster at 15.6% — sustainability is the question.

GILD generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

EOG scores higher overall (80/100 vs 72/100), backed by strong 23.3% margins and 15.6% revenue growth. GILD offers better value entry with a 43.2% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EOG Resources Inc

ENERGY · OIL & GAS E&P · USA

EOG Resources, Inc. is an American energy company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in the Heritage Plaza building in Houston, Texas.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?